Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212947 · ClinicalTrials.gov registry record
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
A clinical trial of Hypochondroplasia, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- 400
- Enrollment target
- 20
- Study locations
NCT06212947: Recruiting study of Hypochondroplasia, sponsored by BioMarin Pharmaceutical.
NCT06212947 is a study of Hypochondroplasia that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 400 participants, above the 95-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (321% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212947, a study of Hypochondroplasia, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
Conditions Studied
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- UCSF Benioff Children's Hospital - Oakland
Missouri
- University of Missouri - Columbia
- Washington University School of Medicine in St. Louis - St Louis
Ohio
- Akron Children's Hospital - Akron
- Nationwide Children's Hospital - Columbus
Arizona
- Phoenix Children's Hospital - Phoenix
Delaware
- Nemours Alfred I. Dupont Hospital for Children - Wilmington
District of Columbia
- Children's National Health System - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- The Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2043-12-31 |
What NCT06212947 shows while recruiting
NCT06212947 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 95-participant average among 4 other Hypochondroplasia trials with a reported enrollment target (321% higher).
The record links to 1 condition, with Hypochondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06212947 names 20 study sites across 17 states, led by California, Missouri, Ohio.
Frequently Asked Questions
What is clinical trial NCT06212947 about?
NCT06212947 is a clinical study titled "A Multicenter Multinational Observational Study of Children With Hypochondroplasia". This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.
What is the current status of trial NCT06212947?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-11-27. Estimated completion is 2043-12-31.
What conditions does trial NCT06212947 study?
This clinical trial studies the following conditions: Hypochondroplasia.
Who is sponsoring clinical trial NCT06212947?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212947 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypochondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Clinical Assessment Study in Children With Hypochondroplasia
RECRUITING
-
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
RECRUITING · Phase 2
-
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
ACTIVE NOT RECRUITING · Phase 3
-
C-Type Natriuretic Peptide and Achondroplasia
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI